Neoadjuvant chemotherapy in relation to long-term mortality in individuals cured of gastric adenocarcinoma
Gastric Cancer · 2025
DOI: 10.1007/s10120-024-01558-7 ↗Kurz gefasst
Fachartikel in der Zeitschrift Gastric Cancer, 2025. Verfasst von Wilhelm Leijonmarck und 2 weiteren Autor:innen. Beteiligte Einrichtung: Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Retzius Street 13A, 4th Floor, 171 77, Stockholm…. Hauptthemen laut MEDLINE: Stomach Neoplasms, Adenocarcinoma, Neoadjuvant Therapy, Gastrectomy. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Vetenskapsrådet, Cancerfonden, Radiumhemmets Forskningsfonder.
Themen: Onkologische Pflege
Abstract (Originalsprache)
Background
Late effects of chemotherapy could affect mortality amongst cancer survivors. This study aimed to clarify if neoadjuvant chemotherapy for gastric adenocarcinoma influences the long-term survival in individuals cured of this tumour.
Methods
This was a nationwide and population-based cohort study that included all individuals who underwent gastrectomy for gastric adenocarcinoma in Sweden between 2006 and 2015 and survived for ≥ 5 years after surgery. The cohort was followed up until death or end of study period (31 December 2020). Multivariable Cox proportional hazards regression was used to provide hazard ratios (HR) with 95% confidence intervals (CI). The HR were adjusted for age, sex, comorbidity, education, calendar year, tumour sub-location, in-hospital complications, and splenectomy. Data came from medical records and nationwide registers.
Results
Amongst 613 gastric adenocarcinoma survivors, neoadjuvant chemotherapy (used in 269 patients; 43.9%) was associated with a decreased crude mortality rate (HR 0.66, 95% CI 0.46–0.96). However, the association attenuated and became statistically non-significant after adjustment for all confounders (HR 0.83, 95% CI 0.56–1.23) and after adjustments solely for age and comorbidity (HR 0.82, 95% CI 0.56–1.20). Stratified analyses did not reveal any statistically significant associations between neoadjuvant chemotherapy and long-term mortality in categories of age, sex, comorbidity, calendar year and tumour sub-location.
Conclusion
Neoadjuvant chemotherapy did not decrease the long-term survival amongst gastric adenocarcinoma survivors. Patients who received neoadjuvant chemotherapy were a selected group characterised by younger age and fewer severe comorbidities and therefore with better chances of long-term survival.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Retzius Street 13A, 4th Floor, 171 77, Stockholm, Sweden. wilhelm.leijonmarck@ki.se.
- Upper Gastrointestinal Surgery, Department of Molecular Medicine and Surgery, Karolinska Institutet, Retzius Street 13A, 4th Floor, 171 77, Stockholm, Sweden.
- School of Cancer and Pharmacological Sciences, King's College London, London, UK.
ORCID-Profile: Wilhelm Leijonmarck
Förderung
- Vetenskapsrådet
- Cancerfonden
- Radiumhemmets Forskningsfonder
- Karolinska Institute
Zitieren
APA
Leijonmarck, W., Mattsson, F., & Lagergren, J. (2025). Neoadjuvant chemotherapy in relation to long-term mortality in individuals cured of gastric adenocarcinoma. Gastric Cancer. https://doi.org/10.1007/s10120-024-01558-7
Vancouver
Leijonmarck W, Mattsson F, Lagergren J. Neoadjuvant chemotherapy in relation to long-term mortality in individuals cured of gastric adenocarcinoma. Gastric Cancer. 2025. doi:10.1007/s10120-024-01558-7
BibTeX
@article{Leijonmarck2025,
author = {Leijonmarck, Wilhelm and Mattsson, Fredrik and Lagergren, Jesper},
title = {Neoadjuvant chemotherapy in relation to long-term mortality in individuals cured of gastric adenocarcinoma},
journal = {Gastric Cancer},
year = {2025},
doi = {10.1007/s10120-024-01558-7}
}
EUVIMED